Intuitive Surgical Inc Stock Moved Up by 3.23% on Feb 13: Key Drivers Unveiled

Intuitive Surgical (ISRG) stock experienced upward movement today, primarily driven by recent positive developments in its product portfolio and robust financial performance.

A significant catalyst for the stock's performance is the recent FDA clearance for the da Vinci 5 robotic system to perform certain cardiac procedures, including mitral valve repair and internal mammary artery mobilization for cardiac revascularization. This strategic regulatory approval expands Intuitive's addressable market into a sector where robotic-assisted surgery penetration has historically been low, signaling new growth opportunities. The enhanced capabilities of the da Vinci 5, including increased computing power, smart instruments, and advanced imaging, are expected to support its measured rollout into these complex cardiac programs.

Furthermore, the company's strong fourth-quarter 2025 earnings, reported on January 22, 2026, continue to provide tailwinds. Intuitive Surgical surpassed Wall Street expectations, reporting adjusted earnings per share and revenue that exceeded consensus estimates. Revenue for the quarter increased by 19% compared to the prior year, driven by approximately 18% growth in worldwide procedures for both da Vinci and Ion systems. The installed base of da Vinci systems grew by 12%, and the Ion endoluminal system saw a 24% increase in its installed base, with Ion procedures growing by approximately 44%. The strong adoption and high utilization rates of the latest da Vinci 5 system also exceeded management's expectations.

Analyst sentiment generally remains positive, with a consensus rating of "Moderate Buy" for ISRG. Although there have been some mixed analyst revisions in recent weeks, many firms have reiterated "Buy" ratings or adjusted price targets upward following the strong earnings report and product advancements, with the median price target implying significant upside. The company's management has also emphasized a focus on sustained earnings strength and aggressive investment in future growth through research and development. These factors collectively contributed to the positive price action observed in Intuitive Surgical shares.

Technically, Intuitive Surgical Inc (ISRG) shows a MACD (12,26,9) value of [-17.61], indicating a sell signal. The RSI at 28.94 suggests sell condition and the Williams %R at -81.37 suggests oversold condition. Please monitor closely.

In terms of media coverage, Intuitive Surgical Inc (ISRG) shows a coverage score of 48.83, indicating a moderate level of media attention, with bullish sentiment.

Intuitive Surgical Inc (ISRG) is in the Healthcare Services & Equipment industry. Its latest annual revenue is 10.06B, ranking 16 in the industry. The net profit is 2.86B, ranking 7 in the industry. Company Profile

Over the past month, multiple analysts have rated the company as BUY, with an average price target of 612.26, a high of 750.00, and a low of 440.00.

Company Specific Risks:

• Anticipated gross margin compression in 2026, driven by headwinds from tariffs (approximately 120-basis-point impact), a higher mix of the da Vinci 5 system, and increased depreciation stemming from facility expansion.
• Intensified competitive dynamics in international markets, particularly with lower tender win rates and pricing intensity in China, coupled with capital spending pressures in Japan and Europe, are expected to weigh on system placements and introduce volatility to international capital sales.
• Recent insider selling activity, indicated by Form 144 filings on February 11, 2026, suggests a potential decrease in confidence from company executives.
• Concerns regarding slowing da Vinci procedure growth, as the company's 2026 guidance for 13-15% worldwide procedure growth is moderated compared to 2025, reflecting broader macroeconomic and market-specific headwinds.